TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16973496

Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols supplementation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise (1-h cycling at 70% VO2max)
Number of subjects: 16
Study: 15469609

Group type: EXPERIMENTAL
Intervention: Behavioural graded activity programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy treatment
Number of subjects: 0
Study: 10661483

Group type: COMPARATOR
Intervention: Standard blood flow and saline flush (125 ml/min and 100 ml once hourly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Augmented blood flow and saline flush (200‐250 ml/min and 100 ml twice hourly)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Red blood cell and platelet transfusion during CRRT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Systemic heparin infusion
Number of subjects: 34
Study: 9310283

Group type: COMPARATOR
Intervention: HIV-1 envelope vaccines (recombinant and synthetic); specific adjuvants include alum plus deoxycholate, MTP-PE, QS21
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Placebo (adjuvant alone or vector with no gene insert/non-HIV gene insert)
Number of subjects: 1398
Study: 8312687

Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 25 mg daily for 7 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 28
Study: 3531308

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Ranitidine treatment in second 4-week period for 124 unhealed patients
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 31562600

Group type: EXPERIMENTAL
Intervention: Surgical margin excision of not more than 2 cm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up data from RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contemporary trial enrolling patients
Number of subjects: 0
Study: 31195357

Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 25774646

Group type: EXPERIMENTAL
Intervention: Postcard intervention (9 postcards over 12 months plus usual treatment)
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 2300
Study: 25850425

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2217

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2217
Study: 23421734

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 62
Study: 21120518

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg kg(‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Caffeine (CAF) and Placebo (PLA)
Number of subjects: 11
Study: 19248105

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injection (2.5 ml)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo injection (2.5 ml)
Number of subjects: 85
Study: 17958934

Group type: EXPERIMENTAL
Intervention: DICOM transmission of stereoscopic images
Number of subjects: 15
Study: 15000637

Group type: EXPERIMENTAL
Intervention: Saturated potassium nitrate/dimethyl isosorbide in aqueous hydroxyethyl cellulose gel
Number of subjects: 0
Study: 11723147

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate meal (25 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normal-carbohydrate meal (65 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (125 g)
Number of subjects: 12
Study: 9340918

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate revascularisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers and platelet aggregation inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE-inhibitors
Number of subjects: 0
Study: 8033658

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) group, 10% Intralipid and 5% Nutrisol‐S for 10‐20 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 3565242

Group type: EXPERIMENTAL
Intervention: Computer-aided dosing (Bayesian forecasting technique)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (unaided physician dosing)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lidocaine concentrations greater than 2 mg/L
Number of subjects: 63
Study: 31852769

Group type: EXPERIMENTAL
Intervention: 30 g FMT
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 60 g FMT
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (own faeces)
Number of subjects: 165
Study: 30871355

Group type: EXPERIMENTAL
Intervention: Clopidogrel early loading (EL) before PCI
Number of subjects: 5438

Group type: EXPERIMENTAL
Intervention: Clopidogrel late loading (LL) after PCI
Number of subjects: 5438

Group type: COMPARATOR
Intervention: Cangrelor
Number of subjects: 5438

Group type: EXPERIMENTAL
Intervention: Clopidogrel early loading (EL)
Number of subjects: 5438

Group type: EXPERIMENTAL
Intervention: Clopidogrel late loading (LL)
Number of subjects: 5438
Study: 28017518

Group type: EXPERIMENTAL
Intervention: Stress-management and muscle relaxation program administered once a week for 1 hour over 3 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 74
Study: 25987072

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium injected 20 min before anesthesia induction (Trial Group I)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium injected 20 min before anesthesia induction and again 12 h after surgery (Trial Group II)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection before anesthesia induction (Control Group)
Number of subjects: 57
Study: 22653766

Group type: EXPERIMENTAL
Intervention: Extrafine beclomethasone dipropionate and formoterol in a combination inhaler
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extrafine formoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional physician diagnosis of exacerbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EXACT (Exacerbations of Chronic Pulmonary Disease Tool)
Number of subjects: 0
Study: 22718671

Group type: EXPERIMENTAL
Intervention: Extract of Valeriana Officinalis L. (765 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (30 mg/day)
Number of subjects: 31
Study: 19384840

Group type: EXPERIMENTAL
Intervention: Olmesartan (initial dose 5 mg, increased to 10 mg, 20 mg, and 40 mg over 16 weeks)
Number of subjects: 25
Study: 23118648

Group type: EXPERIMENTAL
Intervention: Intravenous rHuEPO 300 units/kg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 14623807

Group type: EXPERIMENTAL
Intervention: Water ingestion (16 oz / 473 mL) 5 minutes before tilt-table testing
Number of subjects: 22
Study: 11099602

Group type: EXPERIMENTAL
Intervention: Plasma CO and NO levels in asphyxiated term neonates with HIE
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plasma CO and NO levels in neonates with HIE stage 3
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plasma CO and NO levels in neonates with brain damage and adverse outcome
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy neonates (control group)
Number of subjects: 63
Study: 8783054

Group type: EXPERIMENTAL
Intervention: Acid water (AW) prepared by an electrolysis apparatus, pH 2.7, 30s washing 2X daily for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX) solution, 30s washing 2X daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline solution, 30s washing 2X daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: No washing (control group), 30s washing 2X daily for 7 days
Number of subjects: 12
Study: 1292967

Group type: EXPERIMENTAL
Intervention: GHRH 1‐44 NH2 (30 to 300 micrograms/day, injected subcutaneously every evening for six months)
Number of subjects: 111
Study: 6740489

Group type: EXPERIMENTAL
Intervention: Clinical rotation in different surgical settings
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Order of completion of PMPs
Number of subjects: 104
Study: 30733197

Group type: EXPERIMENTAL
Intervention: Arthroscopic hip surgery
Number of subjects: 222

Group type: COMPARATOR
Intervention: Physiotherapy and activity modification
Number of subjects: 222
Study: 29807228

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 26922462

Group type: EXPERIMENTAL
Intervention: Atomoxetine (25, 40, 60, 80, or 100 mg daily)
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study: 24935221

Group type: EXPERIMENTAL
Intervention: PACE Plus
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: PACE
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1060
Study: 23154439

Group type: EXPERIMENTAL
Intervention: Spiritual Learning Program (SLP), 8 weeks, 50 minutes per week, including lectures, discussion, reflection, and spiritual practices.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spiritual Learning Program (SLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final clinical practice scores from the experimental group
Number of subjects: 0
Study: 20595119

Group type: EXPERIMENTAL
Intervention: Closed intramedullary nailing
Number of subjects: 85

Group type: COMPARATOR
Intervention: Locked compression plate
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 85
Study: 18580552

Group type: EXPERIMENTAL
Intervention: Bilateral electroconvulsive therapy (ECT) at 150% above the measured seizure threshold (ST)
Number of subjects: 80
Study: 15967567

Group type: EXPERIMENTAL
Intervention: 15 mg propiverine twice daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: 2 mg tolterodine twice daily
Number of subjects: 202
Study: 12012145

Group type: EXPERIMENTAL
Intervention: Detailed and clinically relevant data on asthma drug prescribing patterns and a guideline statement
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Aggregate data on asthma drug prescribing patterns and a guideline statement
Number of subjects: 292

Group type: COMPARATOR
Intervention: Feedback on an unrelated subject
Number of subjects: 292
Study: 10386467

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks, followed by a maintenance dose of 240 mg every month
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bilateral orchidectomy
Number of subjects: 17
Study: 8698375

Group type: EXPERIMENTAL
Intervention: Oral fluconazole 150 mg
Number of subjects: 157

Group type: COMPARATOR
Intervention: Topical clotrimazole applied twice daily for 7 days
Number of subjects: 157
Study: 1519716

Group type: EXPERIMENTAL
Intervention: Ibuprofen/codeine combination (400 mg ibuprofen/25.6 mg codeine phosphate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paracetamol/codeine/caffeine combination (1 g paracetamol/16 mg codeine phosphate/60 mg caffeine)
Number of subjects: 30
Study: 6503363

Group type: COMPARATOR
Intervention: Low energy (200 to 240 J)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermediate energy (300 to 320 J)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High energy (400 to 440 J)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 360 J (maximal energy dose available in most defibrillators)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 100
Study: 30409040

Group type: EXPERIMENTAL
Intervention: Lecture at 12:00 (noon condition)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Lecture at 19:30 (evening condition)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Shorter sleep durations and later bedtimes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Longer sleep durations and earlier bedtimes
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Above-median fluid intelligence scores
Number of subjects: 78
Study: 29605103

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29798036

Group type: EXPERIMENTAL
Intervention: Nasal Budesonide combined with fexofenadine hydrochloride (Group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Budesonide combined with montelukast (Group C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nasal Budesonide (Group A)
Number of subjects: 96
Study: 24947722

Group type: EXPERIMENTAL
Intervention: Greater LVM regression (more than median percentage change in LVMi)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Greater LVM regression
Number of subjects: 690

Group type: COMPARATOR
Intervention: Lesser LVM regression
Number of subjects: 690
Study: 22205636

Group type: EXPERIMENTAL
Intervention: Ingestion with mastication (chewing gum)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ingestion without mastication (no chewing gum)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ingestion with mastication
Number of subjects: 14
Study: 19053970

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Open sequential treatment protocol (augmentation with lithium, switch to a monoamine oxidase inhibitor or ECT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Augmentation with lithium
Number of subjects: 81
Study: 17988728

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 9795
Study: 15628051

Group type: EXPERIMENTAL
Intervention: Thiopental, atracurium besilate and fentanyl (Group I; n=27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Propofol, vecuronium bromide and fentanyl (Group II; n=28)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 10891019

Group type: EXPERIMENTAL
Intervention: Psychologists
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Social Workers
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Pediatricians
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Psychologists and Social Workers
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: All Disciplines
Number of subjects: 1242
Study: 9313601

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained-release diltiazem
Number of subjects: 0
Study: 8362305

Group type: EXPERIMENTAL
Intervention: Halofantrine (3 doses of 500 mg at 6 hour intervals)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mefloquine (divided doses of 1,250 mg or 1,500 mg based on weight)
Number of subjects: 55
Study: 3569678

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2721543

Group type: EXPERIMENTAL
Intervention: Midazolam 3.75 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Midazolam (various doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Triazolam 0.25 mg
Number of subjects: 6
Study: 31806653

Group type: EXPERIMENTAL
Intervention: Exenatide (EQW)
Number of subjects: 14752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14752
Study: 31184785

Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBaP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional right ventricular pacing (RVP)
Number of subjects: 44
Study: 27688143

Group type: EXPERIMENTAL
Intervention: Karate training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 55
Study: 25950233

Group type: EXPERIMENTAL
Intervention: Nap group
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wake group
Number of subjects: 34
Study: 22989264

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-fluvastatin (Control)
Number of subjects: 67
Study: 21567070

Group type: EXPERIMENTAL
Intervention: sivelestat (0.2 mg/kg/h from induction of anesthesia to post-operative day 1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: physiological saline (control group)
Number of subjects: 24
Study: 19506392

Group type: EXPERIMENTAL
Intervention: GH treatment (1.3, 2.0, and 2.7 mg/m(2)/day)
Number of subjects: 39
Study: 17034608

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for 1 week before PCNL
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no ciprofloxacin)
Number of subjects: 115
Study: 15328756

Group type: EXPERIMENTAL
Intervention: BN165 (Ginkor Fort)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BN165 (Ginkor Fort) 2 active capsules per day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: BN165 (Ginkor Fort) 3 capsules per day
Number of subjects: 48
Study: 11002713

Group type: EXPERIMENTAL
Intervention: Epidural infusion of alfentanil at T5-7 (group T)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural infusion of alfentanil at L2-3 (group L)
Number of subjects: 30
Study: 9149197

Group type: EXPERIMENTAL
Intervention: Inhaled 35% CO2
Number of subjects: 14

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tensilon 10 mg i.v.
Number of subjects: 14
Study: 8450060

Group type: EXPERIMENTAL
Intervention: Hib PS-OMPC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oligo-CRM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hib PS-T
Number of subjects: 0
Study: 3766854

Group type: EXPERIMENTAL
Intervention: Amoscanate 3.5 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amoscanate 1 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30354784

Group type: COMPARATOR
Intervention: BNS (Misago stent implantation without cilostazol)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: BNS with cilostazol (Misago stent implantation with cilostazol)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (Zilver PTX stent implantation without cilostazol)
Number of subjects: 255
Study: 27566622

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25566620

Group type: EXPERIMENTAL
Intervention: Yindan Xinnaotong Soft Capsule (YXSC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Naoxintong Capsule (NC)
Number of subjects: 118
Study: 21960068

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol-fixed combination (DTFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Brimonidine/timolol-fixed combination (BTFC)
Number of subjects: 60
Study: 20156345

Group type: EXPERIMENTAL
Intervention: Exercise intervention (two specifically tailored supervised moderate intensity aerobic exercise sessions weekly over 8 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 18215592

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 180

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 180

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors or clopidogrel
Number of subjects: 180
Study: 15730347

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg twice daily (n = 34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 69
Study: 14607207

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8 mg once daily
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 10685831

Group type: EXPERIMENTAL
Intervention: leflunomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 9124201

Group type: EXPERIMENTAL
Intervention: TAE plus 5'-DFUR (400 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TAE alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TAE plus 5'-DFUR
Number of subjects: 40
Study: 8087578

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation treatment modalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment protocols
Number of subjects: 0
Study: 3098543

Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31564267

Group type: EXPERIMENTAL
Intervention: Unilateral PKP
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Bilateral PKP
Number of subjects: 178
Study: 27896528

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) (660 ± 20 nm, 3 J/cm2) along with conventional therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 30
Study: 24135258

Group type: EXPERIMENTAL
Intervention: Manager trained
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Manager and staff trained
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 42
Study: 23269370

Group type: EXPERIMENTAL
Intervention: Single-access laparoscopic cholecystectomy (SALC)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 269
Study: 21539702

Group type: EXPERIMENTAL
Intervention: Transforaminal injection of steroids (TFIS)
Number of subjects: 71
Study: 18298236

Group type: EXPERIMENTAL
Intervention: Immediate feedback intervention (PFI)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Delayed feedback intervention (PFI)
Number of subjects: 230
Study: 17038949

Group type: COMPARATOR
Intervention: Narcotics alone (Control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitor in addition to narcotics (Experimental)
Number of subjects: 27
Study: 14522292

Group type: EXPERIMENTAL
Intervention: Trypan blue 0.1% dye (Blurhex) used in Group 2
Number of subjects: 42

Group type: COMPARATOR
Intervention: No trypan blue dye used in Group 1
Number of subjects: 42